Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07105111 · ClinicalTrials.gov registry record · Phase 4

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

A Phase 4 study of Schizophrenia and Major Depressive Disorder, sponsored by Neurocrine Biosciences.

Recruiting
Registry status
Phase 4
Development phase
50
Enrollment target
8
Study locations

NCT07105111 is a Phase 4 study of Schizophrenia and Major Depressive Disorder that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 50 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The trial reports 8 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07105111, a Phase 4 study of Schizophrenia and Major Depressive Disorder, is actively recruiting participants, sponsored by Neurocrine Biosciences.

RECRUITING
Registry status
Phase 4
Development phase
50 participants
Enrollment target
8
Study locations

Study Summary

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Conditions Studied

Schizophrenia Major Depressive Disorder Bipolar Disorder Schizoaffective Disorder Tardive Dyskinesia

Interventions

  • DRUG Valbenazine

Study Locations (8)

Florida

  • Neurocrine Clinical Site - Bonita Springs
  • Neurocrine Clinical Site - Hialeah
  • Neurocrine Clinical Site - Miami
  • Neurocrine Clinical Site - Tampa

California

  • Neurocrine Clinical Site - Fountain Valley
  • Neurocrine Clinical Site - Orange

Arkansas

  • Neurocrine Clinical Site - Bryant

Georgia

  • Neurocrine Clinical Site - Marietta

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-08-29
Est. Completion 2027-04
Phase Phase 4

Sponsor

Neurocrine Biosciences

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07105111

The ClinicalTrials.gov registry entry for NCT07105111 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Valbenazine is the first listed.

NCT07105111 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT07105111 about?

NCT07105111 is a clinical study titled "A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor". This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

What is the current status of trial NCT07105111?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-08-29. Estimated completion is 2027-04.

What conditions does trial NCT07105111 study?

This clinical trial studies the following conditions: Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder, Tardive Dyskinesia.

What interventions are being tested in trial NCT07105111?

The interventions under investigation include: Valbenazine (DRUG).

Who is sponsoring clinical trial NCT07105111?

This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07105111 being conducted?

This trial has 8 study locations across Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Major Depressive Disorder

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.